Expert Opinion on Therapeutic Patents

Papers
(The median citation count of Expert Opinion on Therapeutic Patents is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)
ArticleCitations
Multicomponent reactions (MCR) in medicinal chemistry: a patent review (2010-2020)136
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-1991
Antimicrobial peptides (AMPs): a patent review (2015–2020)50
Repurposing drugs for the management of COVID-1946
Natural compounds and extracts as novel antimicrobial agents45
Antibiotic resistance and bacterial biofilm44
Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010–present)42
Biofilm and Quorum Sensing inhibitors: the road so far39
An updated patent review of VEGFR-2 inhibitors (2017-present)37
Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents36
An updated patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2016–present)36
Acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease – a patent review (2016–present)35
Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016–2020)33
Synthetic molecules as DprE1 inhibitors: A patent review32
The therapeutic potential of PROTACs32
Small-molecule CSF1R kinase inhibitors; review of patents 2015-present32
An updated patent review of anticancer Hsp90 inhibitors (2013-present)31
Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020)29
O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer’s disease and related tauopathies: analysis of the patent literature29
Current trends of benzothiazoles in drug discovery: a patent review (2015–2020)28
Marine natural products as source of new drugs: an updated patent review (July 2018-July 2021)27
TRPV4 antagonists: a patent review (2015–2020)27
Factor XII(a) inhibitors: a review of the patent literature26
Soluble guanylate cyclase stimulators and their potential use: a patent review25
Thioredoxin reductase inhibitors: updated patent review (2017-present)25
Anticancer carbonic anhydrase inhibitors: a patent and literature update 2018-202225
Small molecule agonists of toll-like receptors 7 and 8: a patent review 2014 – 202025
Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020)24
Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2016–2020)24
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)23
Targeting glucose metabolism to develop anticancer treatments and therapeutic patents23
Novel ligands and modulators of triggering receptor expressed on myeloid cells receptor family: 2015-2020 updates23
Ligands for cereblon: 2017–2021 patent overview22
A patent review of transient receptor potential vanilloid type 1 modulators (2014–present)22
Protease inhibitors targeting the main protease and papain-like protease of coronaviruses22
A patent review of topoisomerase I inhibitors (2016–present)21
ATP-citrate lyase (ACLY) inhibitors as therapeutic agents: a patenting perspective21
Steroid sulfatase inhibitors: the current landscape21
Novel matrix metalloproteinase inhibitors: an updated patent review (2014 - 2020)20
Anti-viral activity of thiazole derivatives: an updated patent review20
A patent review of berberine and its derivatives with various pharmacological activities (2016–2020)20
An updated patent review of monoacylglycerol lipase (MAGL) inhibitors (2018-present)20
Inhibitors of type II transmembrane serine proteases in the treatment of diseases of the respiratory tract – A review of patent literature20
Small-molecule CD73 inhibitors for the immunotherapy of cancer: a patent and literature review (2017–present)20
Hypoxia-activated prodrug derivatives of anti-cancer drugs: a patent review 2006 – 202119
Aurora kinase inhibitors: a patent review (2014-2020)18
An updated patent review of autotaxin inhibitors (2017–present)18
Inhibitors of immuno-oncology target HPK1 – a patent review (2016 to 2020)18
Therapeutic approaches targeting the neurotensin receptors18
A patent review of MALT1 inhibitors (2013-present)18
Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature18
JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016–present)18
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present)18
N-heterocyclic carbene metal complexes as therapeutic agents: a patent review17
Recent updates on Wnt signaling modulators: a patent review (2014-2020)17
Targeting the TGF-β signaling pathway for fibrosis therapy: a patent review (2015–2020)17
Soluble epoxide hydrolase inhibitors: an overview and patent review from the last decade17
Phosphoglycerate dehydrogenase (PHGDH) inhibitors: a comprehensive review 2015–202017
Purposing plant-derived exosomes-like nanovesicles for drug delivery: patents and literature review16
An updated patent review on drugs for the treatment of tuberculosis (2018-present)16
Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020)16
Potential of microRNA based diagnostics and therapeutics in glioma: a patent review16
Patent landscape of pediatric-friendly oral dosage forms and administration devices16
Mucormycosis medications: a patent review15
Selective TYK2 inhibitors as potential therapeutic agents: a patent review (2019–2021)15
Small molecule modulators of IL-17A/IL-17RA: a patent review (2013-2021)15
A patent review of adaptor associated kinase 1 (AAK1) inhibitors (2013-present)15
Micro/nanosystems and biomaterials for controlled delivery of antimicrobial and anti-biofilm agents14
Dihydrofolate reductase inhibitors: patent landscape and phases of clinical development (2001–2021)14
Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2020–present)14
An updated patent review of protein arginine N-methyltransferase inhibitors (2019–2022)14
Tankyrase inhibitors as antitumor agents: a patent update (2013 – 2020)14
Butyrylcholinesterase inhibitors as potential anti-Alzheimer’s agents: an updated patent review (2018-present)14
Phosphodiesterase‑4 inhibitors: a review of current developments (2013–2021)13
An updated patent review on monoamine oxidase (MAO) inhibitors13
Inhibitors of RIP1 kinase: a patent review (2016–present)13
TGR5 agonists for diabetes treatment: a patent review and clinical advancements (2012-present)13
Small molecules as kinetoplastid specific proteasome inhibitors for leishmaniasis: a patent review from 1998 to 202113
GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present)13
Tackling prion diseases: a review of the patent landscape13
Small Molecule Inhibitors of Programmed Cell Death Ligand 1 (PD-L1): A Patent Review (2019–2021)13
Searching for effective antiviral small molecules against influenza A virus: A patent review12
Metal organic frameworks (MOFs) with therapeutic and biomedical applications: a patent review12
The patent maze of COVID 19 vaccines11
Menin-MLL protein-protein interaction inhibitors: a patent review (2014–2021)11
Targeting carbonic anhydrases for the management of hypoxic metastatic tumors11
Monocyclic beta–lactams for therapeutic uses: a patent overview (2010–2020)10
A patent review of mTOR inhibitors for cancer therapy (2011–2020)10
A patent review of anticancer CDK2 inhibitors (2017–present)10
Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property10
An updated patent review of Nrf2 activators (2020-present)10
A patent review of MAT2a inhibitors (2018–2021)10
Repositioning and investigational drugs for Zika virus infection treatment: a patent review10
An updated patent review of glutaminase inhibitors (2019–2022)9
Development of tubulin polymerization inhibitors as anticancer agents9
Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (2015-present)9
An updated patent review of Akt inhibitors (2016-present)9
OX40 agonists for cancer treatment: a patent review9
A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022)9
An updated patent review of small-molecule c-Met kinase inhibitors (2018-present)9
Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins9
BET inhibitors: an updated patent review (2018–2021)9
Iron oxide nanoparticles for biomedical applications: an updated patent review (2015–2021)8
Discovery of small-molecule ATR inhibitors for potential cancer treatment: a patent review from 2014 to present8
A patent review on cathepsin K inhibitors to treat osteoporosis (2011 – 2021)8
A patent review of glutaminyl cyclase inhibitors (2004–present)8
Agonist of stimulator of interferon genes as antitumor agents: a patent review (2008-2020)8
A patent review of NLRP3 inhibitors to treat autoimmune diseases8
Malaria transmission blocking compounds: a patent review8
Inhibitory activities of bipyrazoles: a patent review8
Current status and patent prospective of lipid nanoparticle for mRNA delivery8
A patent review of selective CDK9 inhibitors in treating cancer7
A patent review of MAPK inhibitors (2018 – present)7
LSD1 inhibitors for anticancer therapy: a patent review (2017-present)7
Inhibitors of cell cycle checkpoint target Wee1 kinase – a patent review (2003–2022)7
Coronaviruses7
A patent review of ubiquitin-specific protease 7 (USP7) inhibitors (2014-present)6
PDE1 inhibitors: a review of the recent patent literature (2008-present)6
Drugs and nanoformulations for the management of Leishmania infection: a patent and literature review (2015-2022)6
Receptor-interacting protein kinase 1 (RIPK1) inhibitor: a review of the patent literature (2018-present)6
Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer – a review of patent literature6
Factor IX(a) inhibitors: an updated patent review (2003-present)6
Drug discovery targeting p21-activated kinase 4 (PAK4): a patent review6
Recent progress in small molecule TBK1 inhibitors: a patent review (2015– 2020)6
Synthesis and therapeutic delivery approaches for praziquantel: a patent review (2010-present)6
An updated patent review of histone deacetylase (HDAC) inhibitors in cancer (2020 – present)6
Discerning the promising binding sites of S100/calgranulins and their therapeutic potential in atherosclerosis6
Recent progress in the development of β2 adrenergic receptor agonists: a patent review (2015-2020)6
Pharmaceutical price regulation and its impact on drug innovation: mitigating the trade-offs6
Negative allosteric modulators of group II metabotropic glutamate receptors: A patent review (2015 – present)6
0.026319026947021